This article was first published Feb. 5.

By Justin Petrone

Affymetrix last week said fourth-quarter sales swelled 13 percent on increased adoption of its next-generation genotyping platform for genome-wide association studies, as well as "strong" sales of products for copy number studies, custom genotyping, and biomarker discovery and validation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.